|
[1] Noë A, Plum J, Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother, 2005, 55(4): 410-412.
[2] Schröder A R, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 2002, 110:521-529.
[3] Han Y, Lassen K, Monie D, et al. Resting CD4+T cells from human immunodeficiency virus type I (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol, 2004, 78:6122-6133.
[4] Lewinski M K, Yamashita M, Emerman M, et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog, 2006, 2:e60.
[5] Meehan A M, Saenz D T, Morrison J H, et al. LEDGF/p75 proteins with alternative chromatin tethers are functional HIV-1 cofactors. PLoS Pathog, 2009, 5:e1000522.
[6] Greger I H, Demarchi F, Giacca M, et al. Transcriptional interference perturbs the binding of Sp1 to the HIV-1 promoter. Nucleic Acids Res, 1998, 26:1294-1301.
[7] Lenasi T, Contreras X, Peterlin B M. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe, 2008, 4:123-133.
[8] Crampton N, Bonass W A, Kirkham J, et al. Collision events between RNA polymerase in convergent transcription studied by atomic force microscopy. Nucleic Acids Res, 2006, 34(19):5416-5425.
[9] Gallastegui E, Millán-Zambrano G, Terme J M, et al. Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. J Virol, 2011, 85(7):3187-3202.
[10] Pereira L A, Bentley K, Peeters A, et al. A compilation of cellular transcription factor interaction with the HIV-1 LTR promoter. Nucleic Acids Res, 2000, 28(3):663-668.
[11] Tacheny A, Michel S, Dieu M, et al. Unbiased proteomic analysis of proteins interacting with the HIV-1 5'LTR sequence: role of the transcription factor Meis. Nucleic Acids Res, 2012, 40(21):e168.
[12] Miller-Jensen K, Skupsky R, Shah P S, et al. Genetic selection for context-dependent stochastic phenotypes: Sp1 and TATA mutations increase phenotypic noise in HIV-1 gene expression. PLoS Comput Biol, 2013, 9(7):e1003135.
[13] Williams S A, Chen L F, Kwon H, et al. NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J, 2006, 25(1):139-149.
[14] Coiras M, López-Huertas M R, Rullas J, et al. Basal shuttle of NF-κB/ IκB alpha in resting T lymphocytes regulates HIV-1 LTR dependent expression. Retrovirology, 2007, 4:56.
[15] Kim Y K, Bourgeois C F, Pearson R, et al. Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J, 2006, 25(15): 3596-3604.
[16] Bates D L, Barthel K K, Wu Y, et al. Crystal structure of NFAT bound to the HIV-1 LTR tandem kappaB enhancer element. Structure, 2008, 16(5):684-694.
[17] Duverger A, Wolschendorf F, Zhang M, et al. An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol, 2013, 87(4):2264-2277.
[18] Henderson L J, Narasipura S D, Adarichev V, et al. Identification of novel T cell factor 4 (TCF-4) binding sites on the HIV long terminal repeat which associate with TCF-4, β-catenin, and SMAR1 to repress HIV transcription. J Virol, 2012, 86(17): 9495-9503.
[19] Rohr O, Aunis D, Schaeffer E. COUP-TF and Sp1 interact and cooperate in the transcriptional activation of the human immunodeficiency virus type 1 long terminal repeat in human microglial cells. J Biol Chem, 1997, 272(49):31149-31155.
[20] Jenuwein T, Allis C D. Translating the histone code. Science, 2001, 293:1074-1080.
[21] Legube G, Trouche D. Regulating histone acetylatransferases and deacetylases. EMBO Rep, 2003, 4(10):944-947.
[22] Coull J J, Romerio F, Sun J M, et al. The human factors YY1 and LSF repress the human immunodeficiency virus type-1 long terminal repeat via recruitment of histone deacetylase 1. J Virol, 2000, 74:6790-6799.
[23] Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J, 2007, 26(24): 4985-4995.
[24] du Chéné I, Basyuk E, Lin Y L, et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated V-1 transcriptional silencing and post-integration latency. EMBO J, 2007, 26:424-435.
[25] Ding D, Qu X, Li L, et al. Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation. Virology, 2013, 440:182-189.
[26] Kauder S E, Bosque A, Lindqvist A, et al. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog, 2009, 5:e1000495.
[27] Chávez L, Kauder S, Verdin E. In vivo, in vitro and in silico analysis of methylation of the HIV-1 provirus. Methods, 2011, 53(1):47-53.
[28] Palaclos J A, Pérez-Plñar T, Toro C, et al. Long-term nonprogressor and elite controller patients who control viremia have a higher percentage of methylation in their HIV-1 proviral promoters than aviremic patients receiving highly active antiretroviral therapy. J Virol, 2012, 86(23):13081-13084.
[29] Rafati H, Parra Maribel, Hakre S, et al. Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. PLoS Biol, 2011, 9(11):e1001206.
[30] Mahmoudi T. The BAF complex and HIV latency. Transcription, 2012, 3(4):171-176.
[31] Easley R, Carpio L, Dannenberg L, et al. Transcription through the HIV-1 nuleosomes: Effects of the PBAF complex in Tat activated transcription. Virology, 2010, 405(2):322-333.
[32] Sanghvi V R, Steel L F. RNA silencing as a cellular defense against HIV-1 infection: progress and issues. FASEB J, 2012, 26:3937-3945.
[33] Chiang K, Rice A P. MicroRNA-mediated restriction of HIV-1 in resting CD4+ T cells and monocytes. Viruses, 2012, 4:1390-1409.
[34] Omoto S, Fujii Y R. Regulation of human immunodeficiency virus 1 transcription by nef microRNA. J Gen Viro, 2005, 86:751-755.
[35] Klase Z, Kale P, Winograd R, et al. HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol, 2007, 8:63.
[36] Carpio L, Klase Z, Coley W, et al. microRNA machinery is an integral component of drug-induced transcription inhibition in HIV-1 infection. J RNAi Gene Silencing, 2010, 6(1):386-400.
[37] Hidalgo-Estévez A M, González E, Punzón C, et al. Human immunodeficiency virus type 1 Tat increases cooperation between AP-1 and NFAT transcription factors in T cells. J Gen Viro, 2006, 87(6):1603-1612.
[38] Mahmoudi T, Parra M, Vries R G, et al. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem, 2006, 281(29):19960-19968.
[39] Vardabasso C, Manganaro L, Lusic M, et al. The histone chaperone protein nucleosome assembly protein-1 (Hnap-1) binds HIV-1 Tat and promotes viral transcription. Retrovirology, 2008, 5:8.
[40] Massari S, Sabatini S, Tabarrini O. Blocking HIV-1 replication by targeting the Tat-hijacked transcriptional machinery. Curr Pharm Des, 2013, 19(10):1860-1879.
[41] Ott M, Geyer M, Zhou Q. The control of HIV transcription: Keeping RNA polymerase II on track. Cell Host Microbe, 2011, 10(5):426-435.
[42] Kiernan R E, Vanhulle C, Schiltz L, et al. HIV-1 Tat transcriptional activity is regulated by acetylation. EMBO J. 1999, 18(21):6106-6118.
[43] Col E, Caron C, Seigneurin-Berny D, et al. The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat. J Biol Chem, 2001, 276(30):28179-28184.
[44] Dorr A, Kiermer V, Pedal A, et al. Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PACF bromodomain. EMBO J, 2002, 21(11):2715-2723.
[45] Pagans S, Pedal A, North B J, et al. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol, 2005, 3(2):e41.
[46] Crotti A, Lusic M, Lupo R, et al. Naturally occurring C-terminally truncated STAT5 is a negative regulator of HIV-1 expression. Blood, 2007, 109(12):5380-5389.
[47] Mosoian A, Teixeira A, High A A, et al. Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages. J Virol, 2006, 80(18):9200-9206.
[48] Jochmann R, Thurau M, Jung S, et al. O-linked N-acetyl-glucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter. J Virol, 2009, 83(8):3704-3718.
[49] Eberhardy S R, Goncalves J, Coelho S, et al. Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol, 2006, 80(6):2873-2883.
[50] Horiba M, Martinez L B, Buescher J L, et al. OKT18, a zinc-finger protein, regulates human immunodeficiency virus type 1 long terminal repeat through two distinct regulatory regions. J Gen Viro, 2007, 88(1):236-241.
[51] Savarino A, Mai A, Norelli S, et al. ‘Shock and kill’effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology, 2009, 6:52.
[52] Xing S, Siliciano R F. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discovery Today, 2013, 18(11/12):541-551.
[53] Archin N, Margolis D M. Attacking latent HIV provirus: from mechanism to therapeutic strategies. Curr Opin HIV AIDS, 2006, 1:134-140.
|
